3D-QSAR, CoMFA, and CoMSIA of new phenyloxazolidinones derivatives as potent HIV-1 protease inhibitors

Structural Chemistry

Volumn 24, Issue 2, 2013, Pages 433-444

  Abedi, Hamid ^a   Ebrahimzadeh, Homeira ^a   Ghasemi, Jahan B ^b  

^a SHAHID BEHESHTI UNIVERSITY   (Iran)

^b K N TOOSI UNIVERSITY OF TECHNOLOGY   (Iran)

Author keywords

CoMFA; CoMSIA; Contour maps; HIV 1 protease; Modeling; Phenyloxazolidinones; PLS

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84879689812     PISSN: 10400400     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11224-012-0092-1     Document Type: Article

References (29)

1. www.unaids.org. Accessed 3 February 2012
2. http://www.who.int/hiv/mediacentre/news64/. Accessed 3 February 2012
3. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657-670
4. Bandres JC, Wang QF, O'Leary J, Baleaux F, Amara A, Hoxie JA, Zolla-Pazner S, Gorny MK (1998) Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J Virol 72:2500-2504
5. Lapatto R, Blundell T, Hemmings A, Overington J, Wood S, Wilderspin A, Merson JR, Whittle PJ, Danley DE, Geoghegan KF, Hawrylik SJ, Lee SE, Scheld KG, Hobart PM (1989) X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 342:299-302
6. Kramer RA, Schaber MD, Skalka AM, Ganguly K, Wong-Staal F, Reddy EP (1986) HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 231:1580-1585
7. Boggetto N, Reboud-Ravaux M (2002) Dimerization inhibitors of HIV-1 protease. Biol Chem 383:1321-1324
8. TanJ J, Cong XJ, Hu LM, Wang CX, Jia L, Lian XJ (2010) Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov Today 15:186-197
9. Ali A, Reddy GSKK, Cao H, Anjum SG, Nalam MNL (2010) Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. J Med Chem 53:7699-7708
10. Reddy GSKK, Ali A, Nalam MNL, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM (2007) Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2 Ligands in pseudosymmetric dipeptide isosteres. J Med Chem 50:4316-4328
11. Richard D, David E, Jeffrey D (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959-5967
12. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130-4146
13. Golbraikh A, Shen M, Xiao ZY, Xiao YD, Lee KH, Tropsha A (2003) Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des 17:241-253
14. Hemmateenejad B, Javadnia K, Elyasi M (2007) Quantitative structure-retention relationship for the Kovats retention indices of a large set of terpenes: a combined data splitting-feature selection strategy. Anal Chim Acta 592:72-81
15. HCA Manual, SYBYL 7.3 (2006). Tripos, St. Louis
16. Pirhadi S, Ghasemi JB (2010) 3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA. Eur J Med Chem 45:4897-4903
17. Stoyanov K, Walmsley AD (2006) Classification and pattern recognition. In: Gemperline PJ (ed) Practical guide to chemometrics. CRC-Taylor and Francis, Oxford, pp 347-351
18. Clark M, Cramer RD, Opdenbosch NV (1989) Validation of the general purpose tripos 5.2 forcefield. J Comput Chem 10:982-1012
19. Folkers G, Merz A, Rognan D (1993) In: Kubinyi H (ed) 3D-QSAR in drug design, theory, methods and applications. Leiden, ESCOM, pp 583-618
20. Viswanadhan VN, Ghose AK, Revankar GR, Robins RK (1989) Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29:163-172
21. Kamath S, Buolamwini JK (2003) Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitriletyrphostins as EGFR and HER-2 kinase inhibitors. J Med Chem 46:4657-4668
22. Bohm M, Sturzebecher J, Klebe G (1999) Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 42:458-477
23. Wold S, Rhue A, Wold H, Dunn W III (1984) The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAMJ Sci Stat Comput 5:735-743
24. Clark M, Cramer RD III (1993) The probability of chance correlation using partial least squares (PLS). Quant Struct Act Relat 12:137-145
25. BushBL Nachbar RB (1993) Sample-distance partial least squares: pLS optimized for manyvariables, with application to CoMFA. J Comput Aided Mol Des 7:587-619
26. Cramer RD III, Bunce JD, Patterson DE (1998) Crossvalidation, bootstrapping, and partial least squares compared with multipleregression in conventional QSAR studies. Quant Struct Act Relat 7:18-25
27. Wold S (1978) Cross-validation estimation of the number of components in factor and principal components models. Technometrics 20:397-405
28. Golbraikh A, Tropsha A (2002) Beware of q2! J Mol Graphics Model 20:269-276
29. Mao Y, Li Y, Hao M, Zhang S, Ai C (2011) Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors. J Mol Model. doi: 10.1007/s00894-011- 1236-1238